Special Issue "New Aspects of Targeting Cancer Metabolism in Therapeutic Approach"
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: closed (15 January 2021).
Cancer-specific metabolism was discovered about 90 years ago, now known as the Warburg effect. Since then, many researchers looking for a cure to cancer have been thwarted, because most biochemical metabolic pathways had not been discovered at the time.
Recently, cancer therapy has made a significant change by heading toward regulating the immune system, despite the fact that most cancers are not induced by mutation of the immune system. This implies a very important shift in focus, from what causes cancer to how we can cure cancer. The real matter resides in the question of how we can distinguish cancer cells from normal cells.
Cancer metabolism is quickly becoming a major drug target for the treatment of a variety of cancers. Cancer-specific metabolic inhibitor enasidenib has been approved for acute myeloid leukemia therapy (2017) by the US FDA and will likely continue to expand. A series of studies on cancer specific metabolic dependency may find a use for the list of metabolic inhibitors as therapeutic agents. That will be the ultimate answer for how we can kill only cancer cells when systemically mixed with normal cells.
This Special Issue focuses on the connection between cancer-specific metabolism and its possibility as a therapeutic target, with an emphasis on novel inhibitors and new therapeutic possibilities targeting metabolic pathways.
Dr. Soo-Youl Kim
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer metabolism
- anticancer drug
- tumor microenvironment
- cancer therapy
- cancer therapeutic target
- cancer anabolism
- cancer catabolism
- cancer mitochondria
- cancer energy metabolism
- cancer metabolomics